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outcomes with high accuracy. This prediction model has
subsequently been validated with additional 90 patients.
Conclusions: Our investigation demonstrated the potential
use of pharmacogenomics approach: by forecasting drug
efﬁcacy one can select proper therapy prior to treatment.
In the case with CHB patients, this genetic predisposition
factors can be used to select IFN or anti-viral drugs.
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Background/Aims: There are a few studies about the
treatment of patients who develop resistance to entecavir.
The aim of this study was to investigate the effect and safety
of adefovir combined with entecavir (Regimen A) or with
lamivudine (Regimen B) as rescue regimens for entecavir
resistant patients.
Method: Serum samples of 7 lamivudine-refractory patients
underwent viral breakthrough during entecavir therapy were
subjected to direct PCR sequencing or cloning sequencing
assay for HBV genotypic resistance. Genotypic resistant
patients were treated with Regimen A or Regimen B
voluntarily. HBVDNA level, alanine aminotransferase (ALT),
serum creatinine were monitored.
Results: Genotypic resistance to entecavir was observed in
6/7 patients. All 6 patients had rtM204V+rt180M mutations.
Besides, 3 patients had rtT184L mutation; 1 patient had
rtV173L+rtT184L mutation; cloning sequencing showed the
other 2 patients each had two kinds of mutations: one had
S202G and T184L and the other had T184A and T184A+I169T.
Before rescue therapy, the median HBVDNA level was
4.97 log10 copies/ml and 3/6 patients had biochemical
breakthrough (2 in Regimen A and 1 in Regimen B). 4/6
patients received regimen A and 2/6 received regimen B.
The mean follow-up time was 25 weeks (range 22 29) and
5/6 patients ﬁnished 24 weeks follow-up (3/4 in Regimen A
group and 3/4 in Regimen B group). Both regimens were
safe and well tolerated. At week 12, all patients had
HBVDNA level reduce 1 log10 copies/ml and one from each
group had HBVDNA level under the lower limit of detection
of 2.70 log10 copies/ml. For 5/6 patients who ﬁnished 24
weeks follow-up, the mean decreases of HBVDNA level
in Regimen A and B group were 3.43 log10 copies/ml and
2.66 log10 copies/ml. All biochemical breakthrough patients
had biochemical response.
Conclusion: Short term follow-up showed that adefovir plus
entecavir or plus lamivudine rescue therapies are both
effective and safe for patients with entecavir resistance.
And effects of both regimens start as early as 12 weeks
after switching therapy.
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Objective: So far, studies about expression and distribution
of AT1R in human liver tissue have rarely been seen in
China. This study explored the AT1R’s expression at different
stages of type B virus chronic hepatitis, from the state of
type B virus carriers to different stages of liver cirrhosis.
The knowledges of this study could provide the probability
for useing ACEIs and ARBs in treatment of liver ﬁbrosis.
This clinic study explored relationships in between serum
HBVDNA, expression of AT1R mRNA and liver ﬁbrosis.
Methods: Sixty-seven cases in total were enrolled in
our study. Of these cases, forty-two with liver biopsy
specimens by liver punctures during the hospitalization
in the department of gastroenterology from January 2007
to January 2008 because of chronic hepatitis B virus
infection, 13 were liver tissue samples of cirrhotic patients
of chronic hepatitis B from liver operations, and the
other 12 were normal liver tissue from liver leaf excision
because of hepatic hemangioma in the same period. Four
milliliters of fast serum samples from the 67 patients were
obtaind 2 days around liver biopsy or surgery. According
to the diagnostic criteria of Chronic hepatitis and ﬁbrosis
stages in programme to combat viral hepatitis 2000, we
divided the selected cases into 4 groups: S0 1, S2 4, end
stage of cirrhosis group and normal control. Pathological
classiﬁcation in optical microscope were made through
HE and Masson stainings of the liver tissues by parafﬁn
sections. Expression of AT1R in liver tissue were examined
by immunohistochemistry (IHC) and gel electrophoresis
semi -quantitative reverse transcription polymerase chain
reaction (RT-PCR). We made serum HBVDNA quantitative
testing with ﬂuorescence quantitative PCR.
Results: (1) The expression of AT1R in liver tissue. IHC
showed that positive staining of AT1R was yellow or brown in
cytoplasm. Positive cells were mainly located in Disse space
around sinusoid. The shapes of these cells were elliptical or
irregular, with apophysises entering into liver cells, indicat-
ing HSCs. Most of the cells were scatteredly distributed,
and also some of them were clustered. Expressions of
AT1R were signiﬁcantly increased parallel to the aggravated
ﬁbrosis. AT1R were expressed in S0 1, S2 4 and end stage
cirrhosis, but it was weak or no expression in normal liver
tissue. Expressions of AT1R in S0 1 group, S2 4 group and
end stage of cirrhosis group were signiﬁcantly increased as
compared to normal control group (P< 0.01); there were no
statistic differences between S0 1 group and normal control
(P > 0.05); S0 1 and S2 4 group were signiﬁcantly different
(P< 0.01); S0 1 group and end stage of cirrhosis group were
signiﬁcantly different (P< 0.01); S2 4 group and end stage
of cirrhosis group were signiﬁcantly difference (P< 0.05).
(2) The expression of AT1R mRNA in liver tissue. Expressions
of AT1RmRNA in S0 1 group, S2 4 group and end stage of
cirrhosis group were signiﬁcantly increased as compared to
normal control group (P< 0.01); S0 1 group and the normal
control group were no signiﬁcant difference (P> 0.05);
S0 1 group and S2 4 group were signiﬁcantly different
(P< 0.01); S0 1 group and end stage of cirrhosis group were
signiﬁcantly different (P< 0.01); S2 4 group and end stage
of cirrhosis group were signiﬁcantly different (P< 0.01).
(3) The correlation analysis between serum HBVDNA and
liver ﬁbrosis stage. There was no correlation between
HBVDNA level and liver ﬁbrosis stage (r = 0.140, P > 0.05).
(4) The correlation analysis between serum HBVDNA and
AT1R mRNA. There was no correlation between HBVDNA
level and AT1RmRNA (r = 0.014, P > 0.05).
Conclusions: Expressions of AT1R in S0 1 group, S2 4 group
and end stage of cirrhosis group were signiﬁcantly increased
as compared to normal control group (P < 0.01); there were
no statistic differences between S0 1 group and normal
control (P > 0.05); S0 1 and S2 4 group were signiﬁcantly
different (P < 0.01); S0 1 group and end stage of cirrhosis
group were signiﬁcantly different (P < 0.01); S2 4 group and
end stage of cirrhosis group were signiﬁcantly different
(P < 0.05).
1. The expression of AT1R mRNA in liver tissue. Expressions
of AT1RmRNA in S0 1 group, S2 4 group and end stage of
cirrhosis group were signiﬁcantly increased as compared
